ArticleEuropean journal of microbiology & immunology2025
Comparative epidemiology of Ghanaian individuals with molecular proof of Entamoeba histolytica with and without concomitant human immunodeficiency virus infection.
Article in European journal of microbiology & immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Entamoeba histolytica is the causative agent of enteric amebiasis in human patients. Partly controversial hypotheses have been proposed regarding the potential impact of the immunological status of patients as well as HIV (human immunodeficiency virus) positivity on the prevalence and clinical course of amebiasis. Methods: To investigate a potential interplay between the epidemiology of E. histolytica and immunological markers of Ghanaian HIV patients, real-time PCR targeting E. histolytica DNA in stool samples was conducted on a cohort of 595 clinically and immunologically well-characterized adult Ghanaian HIV patients, along with 82 HIV negative control-individuals. Results: E. histolytica DNA was more prevalent in the HIV-negative control group (12.2%, n = 10/82) compared to the HIV-positive subpopulation (3.5%, n = 21/595, P = 0.001). Among HIV-positive individuals, the prevalence of E. histolytica DNA was 4.2% in subjects with CD4+ T cell counts above 200 cells/µL, 3.3% in case of 50 and 200 cells/µL, and 0% in case of less than 50 cells/µL. In the group of ART-exposed HIV-positive individuals, E. histolytica positivity was associated to lower CD4+/CD8+ cell ratios. Conclusions: The study suggested a negative association of E. histolytica DNA detections with HIV-positivity and with the degree of HIV infection-associated immunosuppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.